Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.36 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757321 | 0.95 | NPSR1 (0.48) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL7440708 | 0.93 | NPSR1 (0.47) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL902070 | 0.93 | NPSR1 (0.47) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL9806701 | 0.93 | NPSR1 (0.47) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL3681568 | 0.91 | NPSR1 (0.45) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL5719495 | 0.91 | NPSR1 (0.45) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL71320 | 0.90 | NPSR1 (0.41) | NPSR1LMNACYP4F2CYP4A11FFAR3 | |
| SCHEMBL230256 | 0.87 | NPSR1 (0.48) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL759802 | 0.82 | NPSR1 (0.54) | NPSR1LMNACYP4F2CYP4A11MAPT | |
| SCHEMBL28832911 | 0.80 | OPRM1 (0.40) | NPSR1LMNACYP4F2CYP4A11FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| EP-4551578-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| CN-117677614-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024008610-A1 | MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-11 | — | — | WO | disclosed |
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-11-16 | — | — | US | disclosed |
| CN-116615193-A | Tumoxic acid monoester derivative as selective FABP5 inhibitor, pharmaceutical composition and application thereof | 纽约州立大学研究基金会 | 2023-08-18 | — | — | CN | disclosed |
| EP-4225292-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116514817-A | Heterocyclic compound with AKT kinase inhibition activity, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| WO-2022076820-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-04-14 | — | — | WO | disclosed |
| EP-2781522-A1 | OPTICALLY ACTIVE BISOXAZOLINE COMPOUND, ASYMMETRIC CATALYST, AND METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND USING SAID CATALYST | Sumitomo Chemical Company, Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013105676-A1 | BENZIMIDAZOLE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | WO | disclosed |
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7507742-B2 | Spirocyclic derivatives | PFIZER INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1987019-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007093540-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS 5HT2/D3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PFIZER, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | NPSR1 21/4885LMNA 3403/4885CYP4F2 1723/4885 |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | NPSR1 21/4885LMNA 3403/4885CYP4F2 1723/4885 |
| US-20070129388-A1 | Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid | PDE7A, PDE7B, PDE3A | NPSR1 351/4885LMNA 1941/4885CYP4F2 640/4885 |
| US-20230365488-A1 | TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | FABP5, FABP1, FABP4 | NPSR1 2852/4885LMNA 2197/4885CYP4F2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.